Dong-A ST and Beactica Therapeutics achieve key milestone in their collaboration to develop new cancer treatments

Dong-A ST Co., Ltd. (170900: Korea SE), a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish drug discovery company, today announced that a lead compound meeting certain pre-defined criteria has been selected in their collaborative research programme aimed at developing first-in-class protein–protein interaction inhibitors for a target of therapeutic importance in cancer and other diseases. The milestone transition provides Dong-A ST with exclusive global rights for further development and commercialization of products based on, or derived from, the lead compound. In